Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts
Compass Therapeutics, Inc. (NASDAQ:CMPX) has received a consensus "Moderate Buy" rating from fourteen analysts, with an average 12-month price target of $13.36 among firms that have issued reports. The company operates as a clinical-stage immuno-oncology biotechnology firm, focusing on developing novel therapies like CTX-471 and DSP107. Shares are currently trading around $6.17, with significant institutional investor interest, including increased stakes from Vivo Capital and Suvretta Capital Management.
Compass Therapeutics (CMPX) to Release Quarterly Earnings on Thursday
Compass Therapeutics (NASDAQ:CMPX) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th, 2026. Analysts project a loss of ($0.10) per share for the quarter. The stock has a "Moderate Buy" consensus rating and an average price target of $13.36, with significant institutional investor activity observed in the fourth quarter.
Compass Therapeutics (NASDAQ:CMPX) Raised to "Hold" at Wall Street Zen
Wall Street Zen has upgraded Compass Therapeutics (NASDAQ:CMPX) from a "sell" to a "hold" rating, contributing to an overall "Moderate Buy" consensus from analysts with a target price of $13.00. The company, a clinical-stage immuno-oncology firm, saw its stock open at $6.28, with a market cap of $1.12 billion, and institutional investors collectively own 68.43% of its shares. Several large investors, including Suvretta Capital Management LLC, Vivo Capital LLC, and Vanguard Group Inc., significantly increased their stakes in CMPX during the last quarter.
Craig-Hallum initiates coverage on Compass Therapeutics stock with Buy rating
Craig-Hallum has initiated coverage on Compass Therapeutics (NASDAQ:CMPX) with a "Buy" rating and a $15.00 price target. The firm is confident in the biotech company's approach to developing bispecific antibodies for cancer therapies, highlighting lead asset tovecimig and its potential near-term commercial opportunity. This positive outlook comes despite the stock's significant rally, with other analysts also maintaining bullish ratings and price targets.
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Craig Hallum
Craig Hallum has initiated coverage on Compass Therapeutics (NASDAQ:CMPX) with a "buy" rating and a $15 price target, suggesting a 136.59% upside. This adds to a generally positive analyst outlook, with the company currently holding a "Moderate Buy" consensus rating and an average target price of $13.00. Institutional investors significantly own the stock, with recent stake increases from firms like Suvretta, Vivo, and Vanguard.
Compass Therapeutics, Inc. (CMPX) Stock Analysis: A Biotech With 109% Potential Upside
Compass Therapeutics, Inc. (CMPX) is presented as a promising biotechnology investment with a 109% potential upside, according to analyst targets. Despite being in the clinical-stage with current negative financial metrics typical for its sector, the company focuses on innovative antibody-based therapeutics for oncology. Strong analyst confidence, indicated by 15 buy ratings and no hold or sell ratings, along with an oversold RSI, suggests potential for significant future growth.
Compass Therapeutics stock rises after Craig-Hallum initiates coverage with Buy
Compass Therapeutics' stock increased by 3.1% after Craig-Hallum initiated coverage with a Buy rating and a $15.00 price target. The firm expressed confidence in the company's bispecific antibody approach for cancer therapies, highlighting its lead asset, tovecimig, and promising early-stage pipeline candidates. Despite an 84% rally over the past year, Craig-Hallum anticipates further upside as the company moves towards commercialization and its assets gain clinical validation.
Canaccord Genuity raises Compass Therapeutics stock price target on Phase 2/3 data expectations
Canaccord Genuity increased its price target for Compass Therapeutics (NASDAQ:CMPX) to $13.00 from $10.00, maintaining a Buy rating, based on anticipated positive Phase 2/3 data for their combination therapy. The firm cited a "low bar" for the therapy and manageable safety concerns. Compass Therapeutics is also making progress in its cancer drug pipeline with key survival analyses expected and notable leadership appointments.
Canaccord Genuity raises Compass Therapeutics stock price target on Phase 2/3 data expectations
Canaccord Genuity has increased its price target for Compass Therapeutics (NASDAQ:CMPX) from $10.00 to $13.00, maintaining a Buy rating on the stock. This adjustment is driven by anticipated positive Phase 2/3 data for tovecimig plus paclitaxel, expected by the end of Q1 2026. The firm notes a "low bar" for the combination therapy and manageable safety concerns, with several other analysts also holding positive ratings on the company.
Compass Therapeutics (NASDAQ:CMPX) Sets New 1-Year High - Here's What Happened
Compass Therapeutics (NASDAQ:CMPX) recently hit a new 52-week high, trading as high as $6.71 with significant intraday gains. This surge is supported by broadly positive analyst sentiment, with an average "Moderate Buy" rating and a price target of $12.23, along with substantial institutional accumulation. Hedge funds and other institutions now own approximately 68.43% of the stock, with several prominent firms increasing their stakes.
Compass Therapeutics stock hits 52-week high at 6.51 USD By Investing.com
Compass Therapeutics (CMPX) stock reached a 52-week high of $6.51 USD, marking a nearly 99% surge over the past year. The biotech firm's market capitalization stands at $1.14 billion, with impressive returns over the last six months and year-to-date. Analysts maintain a bullish outlook, with price targets ranging from $8 to $30, supported by significant progress in its cancer drug pipeline and strategic leadership appointments.
Compass Therapeutics stock hits 52-week high at 6.51 USD By Investing.com
Compass Therapeutics (CMPX) stock reached a new 52-week high of $6.51 USD, marking a significant 98.76% surge over the past year and a 116.95% return over six months. The biotech firm and its market capitalization of $1.14 billion is supported by a strong financial position, with analysts setting price targets between $8 and $30. The company also reported progress in its cancer drug pipeline, including upcoming survival analyses for tovecimig and a positive response for CTX-8371, alongside key executive appointments.
Compass Therapeutics stock hits 52-week high at 6.51 USD By Investing.com
Compass Therapeutics' stock (CMPX) has reached a new 52-week high of $6.51 USD, marking a significant surge of 98.76% over the past year. The company, with a market capitalization of $1.14 billion, has seen substantial growth due to strategic advancements and strong investor confidence. Analysts maintain bullish ratings, projecting further upside potential for the biotech firm.
Compass Therapeutics stock hits 52-week high at 6.51 USD
Compass Therapeutics' (CMPX) stock reached a 52-week high of $6.51 USD, reflecting a 98.76% surge over the past year and a market capitalization of $1.14 billion. The biotech firm's growth is supported by a strong financial position and analyst recommendations, with price targets ranging from $8 to $30. Recent advancements in its cancer drug pipeline and strategic leadership appointments further contribute to investor confidence.
Wall Street Zen Upgrades Compass Therapeutics (NASDAQ:CMPX) to "Hold"
Wall Street Zen has upgraded Compass Therapeutics (NASDAQ:CMPX) from a "sell" to a "hold" rating, joining several other firms with "buy" or "outperform" coverage. The company, focused on immuno-oncology therapies, has a "Moderate Buy" consensus rating with a $12.23 target price from MarketBeat. Compass Therapeutics recently reported better-than-expected quarterly EPS and its stock opened at $6.40, with a 12-month trading range of $1.33–$6.49.
Compass Therapeutics (NASDAQ:CMPX) Reaches New 1-Year High - Here's Why
Compass Therapeutics (NASDAQ:CMPX) recently hit a new 52-week high, trading as high as $6.48 and closing at $6.41, representing a 3.6% rise on significant volume. The company, which focuses on immuno-oncology therapies, has a "Moderate Buy" consensus rating from analysts, with an average price target of $12.23. Institutional investors have also been increasing their holdings in the stock.
Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?
Compass Therapeutics, Inc. (CMPX) has gained 20.2% recently, and Wall Street analysts project a potential upside of 113.7% with a mean price target of $13.23. Despite the skepticism often surrounding analyst price targets, a strong agreement on projected earnings improvements among analysts, coupled with a Zacks Rank #2 (Buy), suggests a legitimate upside for the stock. Investors are advised to consider price targets critically but acknowledge the positive trends in earnings estimate revisions.
Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?
Wall Street analysts project an average upside of 113.73% for Compass Therapeutics, Inc. (CMPX), with a mean price target of $13.23. While individual price targets can be misleading, a consensus of positive earnings estimate revisions and a Zacks Rank #2 (Buy) suggest potential near-term upside for the stock. Investors are advised to use price targets as a starting point for research rather than the sole basis for investment decisions.
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Moderate Buy" from Analysts
Compass Therapeutics, Inc. (NASDAQ:CMPX) has received a "Moderate Buy" consensus rating from fifteen analysts, with an average 12-month price target of $12.23. The company has significant institutional ownership, with hedge funds holding approximately 68.43% of the stock. Recent financial results show Compass Therapeutics beat EPS estimates, though analysts anticipate a negative EPS for the current fiscal year.
Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?
Wall Street analysts project an average upside of 113.73% for Compass Therapeutics, Inc. (CMPX), with a mean price target of $13.23. The article highlights that while price targets can be misleading due to analyst optimism, a strong agreement among analysts on higher earnings estimates, indicated by a Zacks Rank #2 (Buy) for CMPX, suggests potential for stock upside. Investors are cautioned to use price targets as a starting point for research rather than the sole basis for investment decisions.
SG Americas Securities LLC Has $523,000 Stake in Compass Therapeutics, Inc. $CMPX
SG Americas Securities LLC significantly reduced its stake in Compass Therapeutics (NASDAQ:CMPX) by 59.9% in Q3, selling 223,368 shares, though institutional ownership remains high at 68.43%. Despite this reduction, other major institutional investors like Vivo Capital and Adage Capital increased their holdings. Analysts maintain a "Moderate Buy" rating with a consensus target price of $12.23, considerably above the current trading price around $5.90.
Compass Therapeutics stock hits 52-week high at 6.25 USD By Investing.com
Compass Therapeutics' stock (CMPX) has reached a new 52-week high of $6.25, reflecting a 128.68% increase over the past year. This surge is attributed to advancements in its therapeutic pipeline, strategic partnerships, and strong analyst recommendations, despite the company not being profitable in the last twelve months. The biotech firm also reported pipeline progress for its cancer drugs and appointed new chief officers, further solidifying investor confidence.
Compass Therapeutics stock hits 52-week high at 6.25 USD
Compass Therapeutics' stock has reached a new 52-week high of $6.25, marking a 128.68% increase over the past year. This growth is attributed to advancements in its therapeutic pipeline, strategic partnerships, and strong fundamentals, despite the company not being profitable in the last twelve months. Analysts have reiterated positive outlooks and price targets for the biotech firm, which also recently made key leadership appointments and reported progress in its cancer drug pipeline.
Compass Therapeutics, Inc. (CMPX): A Bull Case Theory
This article summarizes a bullish thesis on Compass Therapeutics, Inc. (CMPX), a clinical-stage oncology company, highlighting its focused pipeline, strong cash position, and significant institutional and insider ownership. The core value driver is CTX-009, targeting large cancer markets with multi-billion dollar peak sales potential. Upcoming catalysts and recent developments reinforce the optimistic outlook for substantial rerating if clinical success is confirmed.
Assessing Compass Therapeutics (CMPX) Valuation After A Year Of Strong Share Price Momentum
Compass Therapeutics (CMPX) has seen significant share price momentum, with 119.23% total shareholder return over the past year, despite reporting no revenue and a net loss. The article examines CMPX's valuation, noting its price-to-book ratio of 4.8x is near its peer average but high compared to the broader US biotech industry, while a Discounted Cash Flow model suggests the stock is significantly undervalued. It advises investors to consider both metrics and further research due to the company's pre-revenue, loss-making status and reliance on clinical development.
Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen downgraded Compass Therapeutics (NASDAQ:CMPX) from a "hold" to a "sell" rating. Despite this downgrade, the consensus among analysts remains "Moderate Buy" with an average price target of $12.23. The company, a clinical-stage biotechnology firm, is advancing programs like CTX-471 and DSP107, and institutional investors own 68.43% of its stock.
Will Compass Therapeutics’ (CMPX) New Oncology Leaders Redefine Its Path From Pipeline to Commercial Scale?
Compass Therapeutics has appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer, effective January 1, 2026, to bolster its oncology leadership. These new hires bring extensive experience in oncology drug launches and advancing immuno-oncology programs, potentially improving the company's execution capabilities in clinical development and commercialization. While their appointments are an early investment in execution, the company's immediate catalysts remain clinical data readouts, regulatory interactions, and partnering activities.
Will Compass Therapeutics’ (CMPX) New Oncology Leaders Redefine Its Path From Pipeline to Commercial Scale?
Compass Therapeutics has appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer, effective January 1, 2026. These new leaders bring extensive oncology launch and development experience, which could strengthen the company's execution capabilities in clinical trials and commercialization. While their immediate impact on clinical data and deal-making isn't expected, they may help mitigate financing and execution risks, influencing Compass Therapeutics' long-term investment narrative.
Strong Analyst Confidence in Compass Therapeutics (CMPX) Driven by CTX-10726 Advancement
This article highlights strong analyst confidence in Compass Therapeutics (CMPX), particularly due to the advancement of its drug candidate CTX-10726. Analysts from Wedbush, H.C. Wainwright, and Canaccord Genuity have reiterated positive ratings and price targets, indicating optimism about the company's clinical pipeline and future prospects. The development of CTX-10726 is seen as a key driver for this positive outlook.
Compass Therapeutics, Inc. (CMPX) Stock Analysis: Exploring a Biotech Powerhouse with 142.77% Upside Potential
Compass Therapeutics, Inc. (CMPX) is highlighted as a clinical-stage oncology biopharmaceutical company with a substantial 142.77% upside potential, according to analyst ratings. Despite current operating losses typical for biotech firms in R&D, its robust pipeline and unanimous analyst support for its innovative antibody-based therapies suggest significant future growth. Investors are advised to watch clinical milestones and regulatory developments as potential catalysts for its stock.
Compass Therapeutics stock rating reiterated at Market Outperform by Citizens
Citizens has reiterated its Market Outperform rating and $10.00 price target for Compass Therapeutics (NASDAQ:CMPX), citing the company's progress in its clinical pipeline and strong financial position. The stock has shown significant growth, with analysts maintaining a Strong Buy consensus. Key upcoming catalysts include progression-free survival and overall survival data for tovecimig, which is being developed for metastatic colorectal cancer.
Compass Therapeutics reports progress across cancer drug pipeline
Compass Therapeutics (NASDAQ:CMPX) has announced significant progress in its cancer drug pipeline, including key survival analyses for tovecimig in biliary tract cancer on track for late Q1 2026 and a confirmed third response for CTX-8371 in Hodgkin Lymphoma. The company's shares have surged over 215% in the past year, and analysts anticipate sales growth. Compass has also strengthened its leadership team and plans to initiate a Phase 1 study for CTX-10726 in Q1 2026.
CMPX - Compass Therapeutics Inc Latest Stock News & Market Updates
This page provides the latest news and market updates for Compass Therapeutics Inc. (CMPX), focusing on its advancements in novel antibody therapies for cancer. It details clinical trial updates, key leadership appointments, financial results, upcoming investor events, and preclinical data presentations, highlighting the company's pipeline progress and strategic developments.
Compass Therapeutics Provides Corporate Update
Compass Therapeutics provided a corporate update, highlighting significant progress in its clinical-stage pipeline, including the ongoing Phase 2/3 COMPANION-002 study for tovecimig, and advancements in CTX-8371 and CTX-10726. The company also announced key senior leadership appointments and reported an estimated $209 million in cash, providing a runway into 2028. Upcoming milestones include data presentations at major medical conferences and the initiation of new clinical trials.
Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital
D. Boral Capital has reaffirmed its "Buy" rating on Compass Therapeutics (NASDAQ:CMPX), setting a price target of $30.00, significantly higher than the MarketBeat consensus of $12.23. The clinical-stage immuno-oncology biotech, which recently beat its quarterly EPS estimates, specializes in developing novel immuno-oncology therapies with lead programs CTX-471 and DSP107. Institutional investors hold approximately 68.4% of the stock, with notable increases from firms like Vivo Capital and Millennium Management.
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Therapeutics, Inc. (Nasdaq: CMPX) announced inducement grants of stock options to two new employees. Arjun Prasad, the new Chief Commercial Officer, and Cynthia Sirard, the new Chief Medical Officer, each received options to purchase 1,000,000 shares of common stock. These grants were made under the Company’s 2025 Inducement Plan as a material inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Compass Therapeutics Provides Corporate Update
Compass Therapeutics has provided a corporate update highlighting progress across its clinical-stage pipeline, including its bispecific antibodies tovecimig, CTX-8371, and CTX-10726. The company anticipates key survival data for tovecimig in biliary tract cancer in late Q1 2026 and has seen promising responses from CTX-8371 in both solid and hematologic malignancies. Compass also expanded its leadership team and expects its cash and marketable securities of $209 million to provide a runway into 2028.
Which Way Will The Needle Swing For Compass Therapeutics' Biliary Tract Cancer Study?
Compass Therapeutics Inc. (CMPX) is awaiting key secondary endpoint results for its lead drug candidate Tovecimig in a Phase 2/3 study (COMPANION-002) for advanced biliary tract cancer, with top-line data expected in late Q1 2026. The company also has other investigational products in its pipeline, including CTX-471, CTX-8371, and CTX-10726, with upcoming clinical trial milestones in early to mid-2026. CMPX maintains a strong cash position, providing a runway through 2028.
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Therapeutics, Inc. (Nasdaq: CMPX) has granted non-qualified stock options to its newly appointed Chief Commercial Officer, Arjun Prasad, and Chief Medical Officer, Cynthia Sirard, as an inducement to their employment. Each officer received options to purchase 1,000,000 shares of common stock with an exercise price of $5.17 per share, vesting over four years. These grants were made under the Company’s 2025 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care
William Blair initiated coverage on Compass Therapeutics (NASDAQ: CMPX), citing the potential for its lead drug, tovecimig, to become the new standard of care for second-line biliary tract cancer (BTC). Analysts estimate peak worldwide sales of $1.46 billion for tovecimig in BTC, leading to an Outperform rating. The company also received Buy, Market Outperform, and Overweight ratings from Canaccord Genuity, Citizens, and Cantor Fitzgerald respectively in December 2025.
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Therapeutics, Inc. announced incentive stock option grants to two new employees, Chief Commercial Officer Arjun Prasad and Chief Medical Officer Cynthia Sirard. These grants, each for 1,000,000 shares of common stock at an exercise price of $5.17, were made under the Company’s 2025 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4) to attract and retain key talent. The options vest over four years, with a 10-year term, and were approved by the Compensation Committee.
Compass Therapeutics appoints new chief commercial and medical officers
Compass Therapeutics, Inc. (NASDAQ:CMPX) has appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, effective January 1, 2026. These key appointments come as the clinical-stage oncology-focused biopharmaceutical company approaches transformational milestones for its product candidates, including tovecimig for biliary tract cancer. The company has seen significant stock growth and positive analyst coverage, highlighting its advancing therapeutic pipeline.
New leaders join Compass Therapeutics as it advances cancer drugs
Compass Therapeutics (CMPX) has appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer, effective January 1, 2026. These key leadership additions are expected to bolster the company's capabilities as it progresses its oncology pipeline, including the drug tovecimig. The appointments are seen as a strategic move to prepare for potential future commercialization steps, given their extensive experience in oncology drug development and commercialization.
Which Way Will The Needle Swing For Compass Therapeutics' Biliary Tract Cancer Study?
Compass Therapeutics Inc. (CMPX) is awaiting topline data in late Q1 2026 from its COMPANION-002 phase 2/3 study of Tovecimig for advanced biliary tract cancer, which has already met its primary endpoint. The company is also advancing other investigational products, including CTX-471, CTX-8371, and CTX-10726, with several clinical milestones expected throughout 2026. With $220 million in cash and marketable securities as of September 30, 2025, CMPX anticipates a cash runway through 2028.
Compass Therapeutics Announces Key Leadership Appointments
Compass Therapeutics has appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer, effective January 1, 2026. These appointments bring extensive commercial and clinical oncology development experience to the company, particularly in product launches and advancing therapies for challenging cancers like biliary tract cancer. The new leaders will focus on commercial strategy for tovecimig and other pipeline candidates, aiming to bring innovative antibody-based therapeutics to patients.
William Blair Initiates Coverage of Compass Therapeutics (CMPX) with Outperform Recommendation
William Blair has initiated coverage of Compass Therapeutics (CMPX) with an "Outperform" recommendation. Analysts project a significant upside of 142.82% from its latest closing price, with an average one-year price target of $12.55/share. Fund sentiment for CMPX is bullish, with institutional ownership increasing by 37.11% in the last three months.
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of "Moderate Buy" from Brokerages
Compass Therapeutics, Inc. (NASDAQ:CMPX) has received a "Moderate Buy" consensus rating from fifteen brokerages, with an average 1-year target price of $12.23. The clinical-stage immuno-oncology company, which recently beat quarterly EPS estimates, saw its shares open at $5.37 with a market cap of approximately $955 million. Analysts project a -0.36 EPS for the current fiscal year.
Compass Therapeutics files for up to $400 million mixed shelf offering - SEC filing
Compass Therapeutics has filed for a mixed shelf offering of up to $400 million, according to an SEC filing. This type of offering allows a company to sell different types of securities (such as common stock, preferred stock, debt securities, and warrants) over a period of time, providing flexibility for future fundraising needs. The news is likely to be watched by investors as it signals potential future capital raises for the biopharmaceutical company.
Compass Therapeutics' (CMPX) Tovecimig Drives Strong Analyst Sentiment
Analyst sentiment for Compass Therapeutics (CMPX) is strong, driven by positive data for its drug Tovecimig, particularly in biliary tract cancer studies. Canaccord and Citizens JMP both initiated coverage with "Buy" and "Outperform" ratings, respectively, setting a $10 price target. The company anticipates further key data reporting in early 2026 and is preparing for additional clinical trials.
Compass Therapeutics’ (CMPX) Tovecimig Drives Strong Analyst Sentiment
Compass Therapeutics (NASDAQ: CMPX) has garnered strong analyst support, with Canaccord and Citizens JMP initiating "Buy" and "Outperform" ratings, respectively, both targeting $10. Analysts highlight the potential of Tovecimig, especially its positive data in biliary tract cancers, as a key value driver. The company also confirmed ongoing preparations for significant clinical trials, reinforcing its promising pipeline in oncology.
